logo-loader
viewPressure BioSciences Inc.

Pressure BioSciences inks second protein manufacturing contract with multi-billion dollar biotherapeutics company

The deal utilizes Pressure’s BaroFold platform, which is designed to navigate the potentially 5,000-step process of manufacturing proteins

Hand about to sign a contract
The company launched its BaroFold Biopharma Services Business in January 2019 after acquiring the assets of BaroFold Inc in late 2017

Pressure BioSciences Inc (OTCMKTS:PBIO) has landed its second major contract with a multi-billion dollar pharmaceutical company to manufacture a candidate protein drug.

The deal utilizes Pressure’s BaroFold platform, which is designed to navigate the potentially 5,000-step process of manufacturing proteins while avoiding the pitfalls of mistakenly forming aggregate proteins and accidental protein misfolding.

The company launched its BaroFold Biopharma Services Business in January 2019 after acquiring the assets of BaroFold Inc in late 2017. Pressure integrated the Barofold patent portfolio with its own technology to create the service.

READ: Pressure BioSciences launches BaroShear K45 system to manufacture water-soluble CBD

“Our proprietary BaroFold Biopharma Services Business offers us a unique opportunity to enter the estimated $44 billion (by 2026) global bioprocess technology market,” CEO Richard Schumacher said. “In addition to successfully performing contract services for two biopharmaceutical companies since the beginning of 2019, we are also in discussions with three additional biopharmaceutical companies interested in utilizing our proprietary BaroFold services for their protein drug candidates.”

In addition to its BaroFold services, Pressure BioSciences has developed pressure cycling technology, which is used in drug design, and ultra sheer technology, which extends the shelf life of milk and juice by reducing heat exposure in the preservation process.

The South Easton, Massachusetts-based company company’s stock declined 1.6% to $3.05 on Wednesday.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Pressure BioSciences Inc.

Price: 2.19 USD

OTCMKTS:PBIO
Market: OTCMKTS
Market Cap: $4.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences Inc. named herein, including the promotion by the Company of Pressure BioSciences Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Pressure BioSciences PCT instrument deemed ‘essential’ by...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil.  Schumacher explains the company’s PCT...

1 week, 6 days ago

2 min read